To further investigate whether tau-mediated insulin release might be relevant to human patients, the authors focused on individuals with early-onset Alzheimer’s disease (EOAD) and healthy controls. This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.